Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Ill-defined disorder? 843 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 843 reports of Ill-defined disorder have been filed in association with MEPOLIZUMAB (Nucala). This represents 2.0% of all adverse event reports for MEPOLIZUMAB.

843
Reports of Ill-defined disorder with MEPOLIZUMAB
2.0%
of all MEPOLIZUMAB reports
361
Deaths
571
Hospitalizations

How Dangerous Is Ill-defined disorder From MEPOLIZUMAB?

Of the 843 reports, 361 (42.8%) resulted in death, 571 (67.7%) required hospitalization, and 344 (40.8%) were considered life-threatening.

Is Ill-defined disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 843 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Ill-defined disorder?

ACETAMINOPHEN\OXYCODONE (9,780) ACETAMINOPHEN\HYDROCODONE (6,159) TOCILIZUMAB (4,411) RITUXIMAB (4,220) ETANERCEPT (4,202) METHOTREXATE (4,063) ABATACEPT (3,630) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (3,600) LEFLUNOMIDE (3,570) CERTOLIZUMAB PEGOL (3,273)

Which MEPOLIZUMAB Alternatives Have Lower Ill-defined disorder Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Ill-defined disorder Reports All Drugs Causing Ill-defined disorder MEPOLIZUMAB Demographics